Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01660620 | Topical Betaxolol for the Prevention of Retinopathy of Prematurity | PHASE1 | COMPLETED | 23 | — | — | Apr 1, 2011 | Nov 1, 2011 | Jan 3, 2013 | - | — |
babies were monitored and HR/RR monitored and recorded by masked observers, periodically
| Arm | Type | Description |
|---|---|---|
| betaxolol | EXPERIMENTAL | betaxolol 0.25% 2 per day for 3 weeks |
| placebo | PLACEBO_COMPARATOR | masked labeling also 2 per day administration |
| Name | Type | Description |
|---|---|---|
| Betaxolol | DRUG | - |
| topical betaxolol | DRUG | given topically |
Inclusion Criteria: * \<1251 grms birth weight Exclusion Criteria: * ocular defect